Skip to content

Evaluation of the Omnipod DASH in Children and Adolescents With Type 1 Diabetes Mellitus

Evaluation of the Usability and Effect on the Metabolic Control of the Omnipod DASH Insulin Administration System in Children and Adolescents With Type 1 Diabetes Mellitus

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05377385
Enrollment
36
Registered
2022-05-17
Start date
2022-04-13
Completion date
2022-09-01
Last updated
2022-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children, Diabetes Mellitus, Type 1, Metabolic Control, Patient Satisfaction

Keywords

Type 1 diabetes mellitus, child, insulin administration, Omnipod DASH, usability, metabolic control

Brief summary

In this study the usability of the Omnipod DASH insulin administration system is evaluated prospectively by two questionnaires. The effect on the metabolic control is evaluated retrospectively by analysis of data from the medical records of the patients.

Detailed description

In the study the usability of the Omnipod DASH (= insulin patch pump) is evaluated prospectively by two questionnaires. The first questionnaire concerns practical items on the application of the pump (e.g. Is it easy to fill to pod?), the wearing of the pump (e.g. Is it comfortable to wear the pump?) and the comparison with insulin administration with insulin pens or other insulin pumps (e.g. is it less painful to administrate insulin by the Omnipod DASH pump). The second questionnaire asks for possible problems that the patients experienced during the wearing of the pump (e.g. did you experience an allergic skin reaction). The questions are formulated to be answered by a 5-point likert scale. The metabolic control is studied retrospectively from data extracted from the medical records, i.e. the results of the determination of HbA1c and the results from continuous glucose monitoring (CGM) at the start, and after 2, 4 and 6 months of the wearing of the Omnipod DASH insulin pump.

Interventions

BEHAVIORALQuestionnaire

Questionnaire about usability of the Omnipod DASH insulin administration system

Sponsors

Jessa Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children and adolescents with type 1 diabetes mellitus * Patients who started in 2021 with the Omnipod DASH insulin administration system in the Jessa Hospital

Exclusion criteria

* Children and adolescents without type 1 diabetes mellitus * Children and adolescents with type 1 diabetes treated with insulin pens or other insulin pumps

Design outcomes

Primary

MeasureTime frameDescription
Usability of and problems encountered with the Omnipod Dash insulin administration systemThrough study completion, an average of 6 monthsUsability of and problems encountered with the Omnipod Dash insulin administration system is evaluated by 2 home made questionnaire evaluated by a 5 point Likert scale. The first questionnaire includes 3 questions about the application of the pod (e.g. it is easy to place the pod), 7 questions about the wearing of the pod (e.g. the pod doesn't hinder me during sleeping) and 11 questions comparing insulin administration with insulin pens (e.g. insulin administration with the pod is more discrete). The second questionnaire includes 9 questions about possible problems with the Omnipod DASH insulin administration system (e.g. I developped an allergic skin reaction).

Secondary

MeasureTime frameDescription
Metabolic control of type 1 diabetes mellitusBefore and during the first 6 months of wearing the Omnipod Dash insulin administration systemMetabolic control of the type 1 diabetes mellitus measured by HbA1c levels and results from continuous glucose measurement data (e.g. time in range, time below range, time above range).

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026